Article Text

PDF
Research paper
Neurochemical correlates of functional decline in amyotrophic lateral sclerosis
  1. Ian Cheong1,
  2. Dinesh K Deelchand1,
  3. Lynn E Eberly2,
  4. Małgorzata Marjańska1,
  5. Georgios Manousakis3,
  6. Gaurav Guliani4,
  7. David Walk3,
  8. Gülin Öz1
  1. 1 Department of Radiology, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, USA
  2. 2 Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, USA
  3. 3 Department of Neurology, University of Minnesota, Minneapolis, USA
  4. 4 Hennepin County Medical Center and HealthPartners Neuroscience Center, Minneapolis, USA
  1. Correspondence to Ian Cheong, University of Minnesota Twin Cities, Center for Magnetic Resonance Research, Minneapolis, MN 55455, USA; cheo0043{at}umn.edu

Abstract

Objective To determine whether proton magnetic resonance spectroscopy (1H-MRS) can detect neurochemical changes in amyotrophic lateral sclerosis (ALS) associated with heterogeneous functional decline.

Methods Nineteen participants with early-stage ALS and 18 age-matched and sex ratio-matched controls underwent ultra-high field 1H-MRS scans of the upper limb motor cortex and pons, ALS Functional Rating Scale-Revised (ALSFRS-R total, upper limb and bulbar) and upper motor neuron burden assessments in a longitudinal observational study design with follow-up assessments at 6 and 12 months. Slopes of neurochemical levels over time were compared between patient subgroups classified by the rate of upper limb or bulbar functional decline. 1H-MRS and clinical ratings at baseline were assessed for ability to predict study withdrawal due to disease progression.

Results Motor cortex total N-acetylaspartate to myo-inositol ratio (tNAA:mIns) significantly declined in patients who worsened in upper limb function over the follow-up period (n=9, p=0.002). Pons glutamate + glutamine significantly increased in patients who worsened in bulbar function (n=6, p<0.0001). Neurochemical levels did not change in patients with stable function (n=5–6) or in healthy controls (n=14–16) over time. Motor cortex tNAA:mIns and ALSFRS-R at baseline were significantly lower in patients who withdrew from follow-up due to disease progression (n=6) compared with patients who completed the 12-month scan (n=10) (p<0.001 for tNAA:mIns; p<0.01 for ALSFRS-R), with a substantially larger overlap in ALSFRS-R between groups.

Conclusion Neurochemical changes in motor areas of the brain are associated with functional decline in corresponding body regions. 1H-MRS was a better predictor of study withdrawal due to ALS progression than ALSFRS-R.

  • amyotrophic lateral sclerosis
  • motor cortex
  • proton MRS
  • longitudinal
  • 7 tesla
  • biomarker

Statistics from Altmetric.com

Footnotes

  • Contributors IC: acquisition, analysis and interpretation of data, and drafting the manuscript. DKD and LEE: analysis of data and revision of manuscript for intellectual content. MM: interpretation of data and revision of manuscript for intellectual content. GM and GG: acquisition of data and revision of manuscript for intellectual content. DW: study concept and design, acquisition and interpretation of data, and revision of manuscript for intellectual content. GO: study concept and design, interpretation of data, and revision of manuscript for intellectual content.

  • Funding This work was supported by the Bob Allison Ataxia Research Center, the Curt O’Hagan ALS-PLS and ALS-Lou Gehrig Disease funds of the University of Minnesota Foundation, and the National Institute of Neurological Disorders and Stroke (NINDS) (grant R01 NS080816). The Center for Magnetic Resonance Research is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) (grant P41 EB015894) and the Institutional Center Cores for Advanced Neuroimaging award (P30 NS076408). This study was also supported by the National Center for Advancing Translational Sciences (NCATS) award (UL1TR000114). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

  • Competing interests IC, DKD, LEE, MM, GM and GG report no disclosures. DW consults for Acceleron Pharma and receives research support from the ALS Association, Acceleron Pharma, Pharnext and FLEX Pharma. GO received research support from Takeda Pharmaceuticals and NeuroVia.

  • Patient consent Not required.

  • Ethics approval All study participants provided written informed consent. The study was approved by the Institutional Review Board: Human Subjects Committee of the University of Minnesota.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.